Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018, provides an overview of the Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline landscape.
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Non-Alcoholic Steatohepatitis (NASH) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 32, 28, 6, 84, 35 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis (NASH) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H1 2018
Table of Contents
Table of Contents 2
Introduction 7
Non-Alcoholic Steatohepatitis (NASH) - Overview 8
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Development 9
Non-Alcoholic Steatohepatitis (NASH) - Therapeutics Assessment 31
Non-Alcoholic Steatohepatitis (NASH) - Companies Involved in Therapeutics Development 47
Non-Alcoholic Steatohepatitis (NASH) - Drug Profiles 91
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects 478
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products 481
Non-Alcoholic Steatohepatitis (NASH) - Product Development Milestones 482
Appendix 492
List of Tables
Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AdAlta Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Albireo Pharma Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Allergan Plc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Amunix Operating Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Aquinox Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arcturus Therapeutics Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ardelyx Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Arisaph Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Assembly Biosciences Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by AstraZeneca Plc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BASF SE, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Betagenon AB, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bird Rock Bio Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by BLR Bio LLC, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Bristol-Myers Squibb Co, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cadila Healthcare Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cardax Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Carmot Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Catabasis Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Cerenis Therapeutics Holding SA, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ChemoCentryx Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CohBar Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ConSynance Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by CymaBay Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Debiopharm International SA, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dicerna Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dimerix Bioscience Pty Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by DURECT Corp, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Eli Lilly and Co, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enanta Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Enyo Pharma SA, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Exicure Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Forma Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galectin Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galecto Biotech AB, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Galmed Pharmaceuticals Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gemphire Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Genfit SA, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GenKyoTex SA, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Gilead Sciences Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GlaxoSmithKline Plc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by GRI Bio Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by HemoShear Therapeutics, LLC, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by iCo Therapeutics Inc., H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Immuron Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Intercept Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Inventiva, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ionis Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Madrigal Pharmaceuticals Inc., H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Matinas BioPharma Holdings Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by MedImmune LLC, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Merck & Co Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Metacrine Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Naia Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NeuroVive Pharmaceutical AB, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NGM Biopharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nippon Chemiphar Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novartis AG, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by NovaTarg Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Novo Nordisk AS, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Nuevolution AB, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ocera Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Oramed Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pfizer Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Pharmaxis Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Promethera Biosciences SA, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by ProMetic Life Sciences Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Protalix BioTherapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Redx Pharma Plc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Regulus Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by reMYND NV, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Ritter Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Saje Pharma LLC, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sancilio & Company Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sanofi, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Second Genome Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Seres Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Shenzhen HighTide Biopharmaceutical Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Shire Plc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Sprint Bioscience AB, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Synlogic Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Tiziana Life Sciences Plc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by TRACON Pharmaceuticals Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Translate Bio Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Vascular Biogenics Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Verlyx Pharma Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Viking Therapeutics Inc, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Pipeline by Zebra Discovery Ltd, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Dormant Projects, H1 2018 (Contd..2), H1 2018
Non-Alcoholic Steatohepatitis (NASH) - Discontinued Products, H1 2018
List of Figures
Number of Products under Development for Non-Alcoholic Steatohepatitis (NASH), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018
Global Thyroid Gland Disorders Treatment Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 80
Thyroid Gland Disorder Treatment is a kind of treatment method, which aims to The thyroid disorder patients, such as hypothyroidism patients and hyperthyroidism patients. When The thyroid gland does not produce sufficient hypothyroidism or too much hyperthyroidism, The body metabolism and functioning will be disrupted.
The global Thyroid Gland Disorders Treatment market was valued at US$ 2950 million in 2023 and is anticipated to reach US$ 3871.9 million by 2030, witnessing a CAGR o......
Global Brachytherapy Afterloaders, Brachytherapy Seeds Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 98
According to our LPI (LP Information) latest study, the global Brachytherapy Afterloaders, Brachytherapy Seeds market size was valued at US$ 150.8 million in 2023. With growing demand in downstream market, the Brachytherapy Afterloaders, Brachytherapy Seeds is forecast to a readjusted size of US$ 168.1 million by 2030 with a CAGR of 1.6% during review period.
The research report highlights the growth potential of the global Brachytherapy Afterloaders, Brachytherapy Seeds market. Brachyth......
Global Peptide Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 109
According to our LPI (LP Information) latest study, the global Peptide Therapeutics market size was valued at US$ 33800 million in 2023. With growing demand in downstream market, the Peptide Therapeutics is forecast to a readjusted size of US$ 63130 million by 2030 with a CAGR of 9.3% during review period.
The research report highlights the growth potential of the global Peptide Therapeutics market. Peptide Therapeutics are expected to show stable growth in the future market. However, pr......
Global Microbiome Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 155
According to our LPI (LP Information) latest study, the global Microbiome Therapeutics market size was valued at US$ 89 million in 2023. With growing demand in downstream market, the Microbiome Therapeutics is forecast to a readjusted size of US$ 916.3 million by 2030 with a CAGR of 39.5% during review period.
The research report highlights the growth potential of the global Microbiome Therapeutics market. Microbiome Therapeutics are expected to show stable growth in the future market. H......
Global Anti-inflammatory Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 109
According to our LPI (LP Information) latest study, the global Anti-inflammatory Therapeutics market size was valued at US$ 108140 million in 2023. With growing demand in downstream market, the Anti-inflammatory Therapeutics is forecast to a readjusted size of US$ 166150 million by 2030 with a CAGR of 6.3% during review period.
The research report highlights the growth potential of the global Anti-inflammatory Therapeutics market. Anti-inflammatory Therapeutics are expected to show stabl......
Global Enzyme Replacement Therapy Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 113
According to our LPI (LP Information) latest study, the global Enzyme Replacement Therapy market size was valued at US$ 11570 million in 2023. With growing demand in downstream market, the Enzyme Replacement Therapy is forecast to a readjusted size of US$ 29900 million by 2030 with a CAGR of 14.5% during review period.
The research report highlights the growth potential of the global Enzyme Replacement Therapy market. Enzyme Replacement Therapy are expected to show stable growth in the f......
Global Infantile Spasms Therapeutics Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 84
According to our LPI (LP Information) latest study, the global Infantile Spasms Therapeutics market size was valued at US$ 138.9 million in 2023. With growing demand in downstream market, the Infantile Spasms Therapeutics is forecast to a readjusted size of US$ 179.6 million by 2030 with a CAGR of 3.7% during review period.
The research report highlights the growth potential of the global Infantile Spasms Therapeutics market. Infantile Spasms Therapeutics are expected to show stable grow......
Global Hormone Replacement Therapy Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 128
According to our LPI (LP Information) latest study, the global Hormone Replacement Therapy market size was valued at US$ 16090 million in 2023. With growing demand in downstream market, the Hormone Replacement Therapy is forecast to a readjusted size of US$ 17930 million by 2030 with a CAGR of 1.6% during review period.
The research report highlights the growth potential of the global Hormone Replacement Therapy market. Hormone Replacement Therapy are expected to show stable growth in th......
Global Plasma Therapy Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 107
According to our LPI (LP Information) latest study, the global Plasma Therapy market size was valued at US$ 265.3 million in 2023. With growing demand in downstream market, the Plasma Therapy is forecast to a readjusted size of US$ 529.4 million by 2030 with a CAGR of 10.4% during review period.
The research report highlights the growth potential of the global Plasma Therapy market. Plasma Therapy are expected to show stable growth in the future market. However, product differentiation, ......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
